Semax

What it is

Semax is a synthetic heptapeptide analog of ACTH(4-10), developed in Russia as a neuroprotective / nootropic agent.S3

Marketed as

Semax is promoted for focus, cognition, and neuroprotection. Outside its Russian approval, these are marketing claims, not effects established to Western regulatory standards.S1S3

Regulatory status (US)

Semax is not approved by FDA (or the EMA).S1S3 It appears among the peptides in FDA's Category 2 compounding review and is on the agenda for the July 2026 Pharmacy Compounding Advisory Committee.S1S2 In the US it is otherwise treated as a research peptide.S3

Around the world

Semax is approved in Russia (and appears on the Russian list of essential medicines) for indications such as ischemic-stroke recovery and cognitive impairment, but is not approved in the US or EU.S3

Evidence

Reported mechanisms include melanocortin, BDNF/NGF, and monoaminergic pathways, and Russian studies describe cognitive and neuroprotective effects.S3 The evidence base is largely Russian with limited independent replication (see caveat), so these effects should not be presented as established to Western standards.S3

Anti-doping

Semax is a nootropic peptide rather than a GH secretagogue; its specific anti-doping status should be checked against the current WADA List rather than assumed.S1

Safety

As an unapproved research peptide in the US, Semax has limited independent long-term safety data, and use falls outside FDA finished-drug oversight; FDA's general Category 2 concerns apply.S1S3

What's changing

The near-term item is the July 24, 2026 PCAC review and any subsequent FDA decision on Semax's compounding status.S1S2